IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.083 |
52 Week High | AU$0.15 |
52 Week Low | AU$0.039 |
Beta | 3.21 |
1 Month Change | -20.95% |
3 Month Change | -20.95% |
1 Year Change | -33.60% |
3 Year Change | -57.44% |
5 Year Change | 388.24% |
Change since IPO | -14.87% |
Recent News & Updates
Recent updates
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Sep 19We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
May 30Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Jan 30Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More
Nov 11Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans
Aug 22Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Feb 28A Look At Imugene's (ASX:IMU) CEO Remuneration
Feb 17Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
Dec 24Shareholder Returns
IMU | AU Biotechs | AU Market | |
---|---|---|---|
7D | 6.4% | 2.8% | 0.9% |
1Y | -33.6% | -8.0% | 5.7% |
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -8% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
IMU volatility | |
---|---|
IMU Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.5% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IMU's share price has been volatile over the past 3 months.
Volatility Over Time: IMU's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.
Imugene Limited Fundamentals Summary
IMU fundamental statistics | |
---|---|
Market cap | AU$607.54m |
Earnings (TTM) | -AU$89.24m |
Revenue (TTM) | AU$15.03m |
40.4x
P/S Ratio-6.8x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMU income statement (TTM) | |
---|---|
Revenue | AU$15.03m |
Cost of Revenue | AU$0 |
Gross Profit | AU$15.03m |
Other Expenses | AU$104.27m |
Earnings | -AU$89.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.012 |
Gross Margin | 100.00% |
Net Profit Margin | -593.63% |
Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparison